Scientific Advisory Board
W. Virgil Brown, M.D.
Charles Howard Candler Professor of Medicine, Emory University
Dr. Brown is the Past President of the American Heart Association (1991-1992) and Past President of the National Lipid Association (2003-2005). He is also the editor of The Journal of Clinical Lipidology. Dr. Brown is well known for his research that began at the National Institutes of Health (NIH) where he served as chairman of the Metabolism Study Section. He is the founder of the prestigious Southeast Lipid Research Forum (instituted in 1992) and has chaired several Gordon Conferences on Lipid Metabolism. Dr. Brown was the recipient of the Golden Heart Award, the highest honor given by the American Heart Association for service to its mission over a lifetime.
Bobby V. Khan, M.D., Ph.D.
Executive Director, Atlanta Vascular Research Foundation
Dr. Khan is one of the founders of InVasc Therapeutics. He was the Director of Cardiovascular Research and Supervisor of the Vascular Research Laboratory at Emory/Grady Memorial Hospital in Atlanta, GA. In 2009, Dr. Khan was awarded a Fulbright Research Chair at the University of Prince Edward Island in Canada. He has published over 60 peer-reviewed papers, served as the principal investigator for several Phase II clinical trials and as a reviewer for several prestigious medical journals. Dr. Khan has also served on several planning committees for the scientific sessions of the American College of Cardiology and the American Heart Association, as well as on the scientific advisory boards of Sanofi-Aventis, Dai-Ichi Sankyo and Bristol Myers Squibb. He has received grant support from the National Institutes of Health, Pfizer, Novartis, Amgen, Boehringer Ingelheim and Forest Pharmaceuticals.
Sampath Parthasarathy, Ph.D., MBA
Professor of Cardiovascular Sciences, University Of Central Florida, College Of Medicine
Dr. Parthasarathy currently holds an endowed chair in Cardiovascular Sciences at the university of Central Florida and is one of InVasc Therapeutics' founders. Dr. Parthasarathy is internationally-recognized for his work in the area of atherosclerosis and has been continually funded by the National Institutes of Health. As one of the originators of the oxidative hypothesis of atherosclerosis, he is credited with the co-discovery of oxidized low-density lipoprotein (ox-LDL) and has published extensively on oxidative stress in chronic diseases including atherosclerosis and endometriosis. He has been extensively involved in drug discovery and been a consultant for numerous major pharmaceutical companies including Bristol Myers Squibb, Johnson & Johnson and Vyrex Pharmaceuticals. Dr. Parthasarathy synthesized and patented water-soluble probucol at the University of California in San Diego and it was this compound that later formed the basis for AGI-1067 which was the lead product for Atherogenics, a pharmaceutical company based in Alpharetta, Georgia that raised nearly $700 million to advance this product. Dr. Parthasarathy holds several patent rights and has designed many of the key agents that are under investigation at InVasc Therapeutics.
Bertram Pitt, M.D.
Professor of Medicine, University of Michigan
Dr. Pitt is an acknowledged leader in the field of Cardiology and in pivotal international clinical trials. He was the principal investigator in the landmark RALES study on heart failure and PLAC study on atherosclerosis. Dr. Pitt has published over 300 papers in his professional career. He is also well-acknowledged by his consulting experiences with multiple pharmaceutical companies including: Pfizer, Takeda, Merck, Dai-Ichi Sankyo, Bayer, Boehringer-Ingelheim, Schering Plough and Astra Zeneca.
Dr. Sanjay Rajagopalan.M.D., Ph.D.
John W. Wolfe Professor of Medicine, Ohio State University
Dr. Rajagopalan is the Director of Vascular Medicine and Co-Director of Cardiovascular CT and MR Imaging at The Ohio State University School of Medicine and is one of InVasc Therapeutics' founder. He is a recognized expert in atherosclerotic vascular disease and has been involved for more than a decade in novel treatment strategies for atherosclerosis and at the forefront of bringing novel therapies to the clinic. Dr. Rajagopalan has been the national principal investigator for Phase I and II clinical trials involving emerging pharmacotherapies for atherosclerosis and is widely sought for his expertise in clinical trial design for lower extremity vascular disease. His expertise in vascular biology and imaging of atherosclerosis provides a unique strength for the imaging based design of pre-clinical and clinical studies targeting this disorder. Dr. Rajagopalan's laboratory currently focuses on understanding risk factors for atherosclerosis and the use of novel therapies to regress plaque. He has published more than 100 manuscripts, and over 125 scientific abstracts. He is currently a member of the Clinical Cardiovascular Science (CCVS) study section of the National Institutes of Health and is on the editorial board for Journal of the American College of Cardiology's Imaging Journal besides being a regular reviewer for multiple leading scientific journals.
George L. Bakris, M.D.
Professor of Medicine, University of Chicago, Pritzker School of Medicine
Dr. Bakris has published over 500 articles and book chapters in the areas of diabetic kidney disease, hypertension and progression of nephropathy. He is the Editor or Co-Editor of eight books, in the areas of Kidney Disease Progression and Diabetes. He chaired the first National Kidney Foundation Consensus report on blood pressure and impact on renal disease progression (2000). He serves as a Special Government Employee for the Food and Drug Administration (FDA) and is on the Board of the National Kidney Foundation. Dr. Bakris is also the past-president of the American College of Clinical Pharmacology (2000-2002) and the current President of the American Society of Hypertension (ASH)-(2010-2012). He is the current Editor of The American Journal Nephrology, the Hypertension Section Editor of Up-to-Date and an Associate Editor of Diabetes Care.
Gordon H. Williams, M.D.
Professor of Medicine, Harvard Medical School
Dr. Williams has published more than 500 original articles, reviews, chapters, and books. His research activities have focused on the genetics of complex diseases involving hormonal mechanisms, specifically hypertension and diabetes mellitus. He was the founder and, until 2008, Director of its Scholars in Clinical Science Program (SCSP), which leads to a master’s degree. Dr. Williams is the Director of the Harvard CTSA (Catalyst)’s Translational Technologies Research Program. He is also the Director of the following activities at the Brigham & Women’s Hospital: the Center for Clinical Investigation; the Human Research Center (HRC); and the Hormonal Mechanisms of Cardiovascular Injury Laboratory. Concurrently he is Chief, Cardiovascular Endocrinology Section. Dr. Williams received the 2008 Robert Tigerstedt Distinguished Scientist Award of the American Society of Hypertension, the 2009 E. H. Ahrens Distinguish Clinical Investigator Award of the Association of Patient Orient Research and the 2010 Clinical Research Prize of the American Heart Association.
